4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-26-149725
Chief Development Officer sold 360 shares at $34.90 ($12,564)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Yeleswaram Krishnaswamy Chief Development Officer | 2026-04-08 | Sale 10b5-1 | −360 | $34.90 | $12,564 | 286,516 | D: show line 1 in the form |
| Open-market sales · 360 sh · avg $34.90 · $12,564 | |||||||
Loading xslF345X06/ownership.xml…